CHD1L knockdown suppresses bladder cancer cell growth in vitro

Author:

Xu Feng1,Shi Xiuquan2,Wang Zuheng1,Chen Yuhao1,Xu Xiaofeng1,Liu Zhe1,Shi Changjie1,Li Ping1,Liu Youhuang1,Zhang Tingling1,Fu Dian1,Ge Jingping1,Cheng Wen2

Affiliation:

1. Department of Urology, Jinling Clinical Medical College of Nanjing Medical University

2. Department of Urology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University

Abstract

Abstract Purpose CHD1L is a DNA helicase protein which is involved in recombinant chromatin and DNA damage repair. As a oncogene, how CHD1L was expressed and functioned in human bladder cancer cells were still not clear. This study was conducted to investigate how CHD1L is expressed and functions in human bladder cancer cells. Materials and methods We detected the expression level of CHD1L in human bladder cancer 5637 cells using qPCR. Through transfecting shCHD1L-harboring lentivirus and constructing CHD1L-knockdown cell models, MTT assay and flow cytometry assay were employed to detect the changes in cell proliferation, cell cycle and cell apoptosis, respectively. Cellular ability of migration was then tested using wound-healing assay and Transwell assay. Results We found that CHD1L was upregulated in bladder cancer 5637 cells. Knocking down CHD1L blocked cell cycle in G1/S transition and thus suppressed cell proliferation and cell migration, but accelerated cell apoptosis. Further exploration in the molecular mechanism indicated that dysfunctions of shCHD1L-harboring cells resulted from CHD1L downexpression may be involved in the reduction of phosphorylation levels of AKT and ERK proteins. Conclusions This study highlighted the tumor-promoting role of CHD1L played in bladder cancer cells, which provided a primary insight into further and deeper on related topics.

Publisher

Research Square Platform LLC

Reference19 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray F;CA: a cancer journal for clinicians,2018

2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: a cancer journal for clinicians 2021; 71: 7–33.

3. Epidemiology of bladder cancer;Malats N;Hematology/oncology clinics of North America,2015

4. Identification of an immunotherapy-responsive molecular subtype of bladder cancer;Song BN;EBioMedicine,2019

5. Emerging Targeted Therapy for Bladder Cancer;Thibault C;Hematology/oncology clinics of North America,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3